Health care investor Water Street Healthcare Partners reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for cardiovascular medication Bivalirudin in 0.9% Sodium Chloride Injection (bivalirudin) following its strategic partnership with a medical products company.
The US FDA approval of bivalirudin marks the fifth drug product successfully developed by Water Street's company, Celerity Pharmaceuticals LLC.
The company said bivalirudin is the first presentation in a frozen, premixed, ready-to-use formulation.
In conjunction, Celerity both funded and led the development and approval of bivalirudin through its strategic partnership with the medical products company.
Upon the US FDA approval of bivalirudin, Celerity transferred ownership to its partner, which will commercially launch the new product in the US.
AstraZeneca announces grant of PRIME eligibility by EMA for MEDI8897
AstraZeneca reports grant of Breakthrough Therapy Designation by US FDA for MEDI8897
Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant
Valbiotis Expands Board of Directors with the Appointment of Murielle Cazaubiel
AstraZeneca's Forxiga receives positive opinion from EU CHMP
Alexion, Caelum Biosciences Team to Develop Targeted Therapy for Light Chain Amyloidosis
Inotrem Extends Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases